Topical Prednisolone Acetate 1%
ApprovedUNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Non-infectious Anterior Uveitis
Conditions
Non-infectious Anterior Uveitis
Trial Timeline
Jul 1, 2020 → Mar 31, 2021
NCT ID
NCT04426734About Topical Prednisolone Acetate 1%
Topical Prednisolone Acetate 1% is a approved stage product being developed by Ocular Therapeutix for Non-infectious Anterior Uveitis. The current trial status is unknown. This product is registered under clinical trial identifier NCT04426734. Target conditions include Non-infectious Anterior Uveitis.
What happened to similar drugs?
1 of 6 similar drugs in Non-infectious Anterior Uveitis were approved
Approved (1) Terminated (2) Active (3)
🔄FAI Insert administered using the Mk II inserter + FAI Insert administered using the Mk I inserterEyePoint PharmaceuticalsPhase 3
🔄ADX-102 Ophthalmic Solution (0.5%) + Vehicle of ADX-102 Ophthalmic SolutionAldeyra TherapeuticsPhase 3
Hype Score Breakdown
Clinical
20
Activity
4
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04426734 | Approved | UNKNOWN |
Competing Products
10 competing products in Non-infectious Anterior Uveitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Adalimumab | AbbVie | Approved | 43 |
| LFG316 + Conventional Therapy | Novartis | Phase 2 | 35 |
| AIN457 + Placebo | Novartis | Phase 3 | 32 |
| AIN457 + AIN457 + AIN457 + Placebo | Novartis | Phase 3 | 32 |
| AIN457 + AIN 457 + AIN457 | Novartis | Phase 2 | 35 |
| ESK-001 | Alumis | Phase 2 | 21 |
| FAI insert + Sham injection | EyePoint Pharmaceuticals | Phase 3 | 34 |
| FAI Insert administered using the Mk II inserter + FAI Insert administered using the Mk I inserter | EyePoint Pharmaceuticals | Phase 3 | 34 |
| ADX-102 Ophthalmic Solution (0.5%) + Vehicle of ADX-102 Ophthalmic Solution | Aldeyra Therapeutics | Phase 3 | 30 |
| NS2 + Prednisolone acetate ophthalmic suspension (1%) | Aldeyra Therapeutics | Phase 2 | 25 |